Qbic

Qbic (Qbic Venture Partners) is a prominent inter-university venture capital fund based in Belgium that specializes in transforming technological breakthroughs from its partner universities and research institutes into sustainable life science and deep tech businesses. Acting as both a seed investor and a venture builder, the firm manages several funds (Qbic I, II, and III) and maintains strategic partnerships with institutions such as VIB, imec, and VITO to identify promising research for commercialization. Its portfolio includes a wide range of innovative biotech companies, such as MRM Health, Confo Therapeutics, Tanai Therapeutics, and Flindr Therapeutics, which are developing therapies for diverse indications including obesity, inflammatory diseases, and oncology. Through its hands-on approach, Qbic provides early-stage coaching and capital to help spin-off companies navigate the transition from laboratory research to clinical development. The firm is a central player in the Belgian and broader European biotechnology ecosystem, supporting over 50 portfolio companies across multiple sectors.